Teva Pharmaceutical's New Study Shows Lasting Relief For Inflammatory Bowel Disease Patients

Positive Data From Inflammatory Bowel Disease StudyTeva and Sanofi SA (NASDAQ:SNY) released positive results on Tuesday from the RELIEVE UCCD long-term extension study of duvakitug, an investigational human monoclonal antibody targeting TL1A.The study demonstrated durable clinical efficacy maintained over 44 weeks in patients with ulcerative colitis and Crohn’s disease.The study involved 130 patients who initially responded to duvakitug in the induction phase, and both doses of duvakitug were well tolerated ...